Scott Gottlieb, MD, Appointed as New FDA Commissioner

VBCR - June 2017, Vol 6, No 2 - FDA Approvals, News & Updates

In early May 2017, the US Senate voted 57 to 42 to appoint Scott Gottlieb, MD, as the 23rd Commissioner of the FDA. Dr Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs, and as Senior Advisor to the FDA Commissioner. In 2013, he was appointed as a member of the federal Health Information Technology Policy Committee, a group that advises the US Department of Health & Human Services on issues pertaining to healthcare information technology issues. He also served as a Senior Advisor to the Administrator of the Centers for Medicare & Medicaid Services, where he worked on implementing the Medicare drug benefits.

In a recent press statement, American College of Rheumatology (ACR) President Sharad Lakhanpal, MBBS, MD, voiced support for Dr Gottlieb in his new role.

“The ACR congratulates Dr. Scott Gottlieb on his confirmation as FDA Commissioner. As prescribing doctors, rheumatologists share Commissioner Gottlieb’s goal of optimizing FDA biosimilar and generic drug approvals to increase competition, lower costs, and improve our patients’ access to safe and proven therapies,” Dr Lakhanpal said. He also emphasized the importance of adequately funding the FDA to ensure that biosimilars reach the patients who need them.

“The FDA continues to play a critical role in lowering biologic drug costs as it works to bring safe, effective, and lower-cost biosimilar alternatives to the marketplace. Therefore, it is imperative that FDA have the funding and resources it needs to expedite biosimilar drug approvals, hire and retain qualified staff, issue guidance, and perform adequate post-market surveillance,” he stated.

Related Items
FDA News - December 2017
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in FDA Approvals, News & Updates
FDA News - October 2017
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in FDA Approvals, News & Updates
New Drugs Approved for Giant-Cell Arteritis and Moderate-to-Severe Rheumatoid Arthritis
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in FDA Approvals, News & Updates
FDA Releases Draft Guidances on Sharing Healthcare Economic Information, Industry Communication Regulations
Leslie Wyatt
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in FDA Approvals, News & Updates
FDA News - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in FDA Approvals, News & Updates
FDA Approves First Tissue-Engineered Autologous Cellularized Scaffold Product for the Repair of Cartilage Defects
Web Exclusives published on December 15, 2016 in FDA Approvals, News & Updates, In the News
FDA News - November 2016
VBCN - November 2016 Volume 3, No 3 published on November 22, 2016 in FDA Approvals, News & Updates
Abuse-Deterrent Oxycodone Extended-Release Capsules Approved for Chronic Pain
Web Exclusives published on November 7, 2016 in FDA Approvals, News & Updates, In the News
FDA News - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in FDA Approvals, News & Updates
Adalimumab Biosimilar Approved for Multiple Inflammatory Indications
Web Exclusives published on September 27, 2016 in FDA Approvals, News & Updates, In the News
Last modified: July 13, 2017
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology